Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs PPG Industries, Inc. (PPG) Price & Performance

Neurocrine Biosciences IncTrade
PPG Industries, Inc.Trade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs PPG Industries, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while PPG Industries, Inc. trades at $105.43 (market cap $23.36B). The key difference: PPG Industries, Inc. is the larger of the two by market cap, and PPG Industries, Inc. pays a 2.82% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and PPG Industries, Inc. for 68 Days on average.

NBIXPPG
Market Cap
$14.60B$23.36B
Volume
1,075,6941,972,399
Sector
HealthBasic Materials
52-Week High
$185.50$131.56
52-Week Low
$123.10$94.34
Typical Hold Time
23 Days68 Days
Enterprise Value
$14.61B$29.22B
Dividend Yield
—2.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.

The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.

PPG Industries, Inc.

PPG trades at $105.45, down 1.02% on the day, with a bearish technical signal from moving averages. The stock shows mixed earnings performance, missing Q4 2025 and Q2 2026 estimates but beating in Q1 2026. Fundamentals are solid with a P/E of 15.08, net income margin of 9.57%, and strong cash flow generation of $1.94B from operations in 2025. Recent news highlights margin pressures in the Automotive Refinish segment and upcoming Q3 2026 earnings on October 27.

The outlook is cautiously optimistic given analyst consensus favoring Buy with a $130 price target, implying 23% upside. Key opportunities include earnings growth and dividend stability, while risks involve segment-specific weakness and macroeconomic headwinds affecting demand. The stock's current valuation near support levels may attract value investors awaiting clearer earnings momentum.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NBIX

No sentiment data available yet.

PPG
100% Buy0% Sell
Avg holding period · 68 Days

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX →

About PPG Industries, Inc.

PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.

Read more on PPG →